IFPA and WHO Foundation Collaborate on Psoriasis
Analysis based on 8 articles · First reported Feb 10, 2026 · Last updated Feb 10, 2026
This collaboration is expected to positively impact the healthcare market by strengthening global understanding and care for psoriasis, potentially leading to increased research and development in treatments. It will also foster better data collection and policy tools, which could influence pharmaceutical and biotechnology sectors.
The International Federation of Psoriasis Associations (IFPA) and the WHO Foundation have signed a multi-year collaboration agreement to support the World Health Organization's efforts in strengthening global understanding, diagnosis, and care for psoriasis. This initiative aims to improve outcomes for over 100 million people worldwide affected by this chronic noncommunicable disease. Key areas of focus include strengthening evidence, updating knowledge and policy tools, and improving access to diagnosis and care. The collaboration will also involve revising the Global Report on Psoriasis, incorporating new prevalence data, scientific advances, and treatment developments since 2016. Additionally, the partnership will work on sharing evidence-based guidance, developing AI-driven diagnostic tools, and training healthcare professionals to manage the disease more effectively. This agreement is seen as a pivotal moment for the global psoriasis community, addressing issues of delayed diagnosis, unequal access to care, and the stigma associated with the condition.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard